Results 131 to 140 of about 3,096 (189)

Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab. [PDF]

Oncol Ther
Di Lorenzo G, Di Maio M, Buonerba C.
europepmc   +1 more source

Desquamative extravasation reaction secondary to enfortumab vedotin

JAAD Case Reports
Akshay N. Pulavarty, MD, MPH, Shane Meehan, MD, Jason Weed, MD   +2 more
doaj   +1 more source

Safety of Enfortumab Vedotin Plus Pembrolizumab in Hemodialysis Patients With Metastatic Urothelial Carcinoma: Case Report. [PDF]

Cancer Diagn Progn
Mizuno T, Kobari Y, Ito H, Yoshino M, Nakamura K, Ikeda T, Nakayama T, Minoda R, Wada A, Fukuda H, Yoshida K, Iizuka J, Ishida H, Takagi T.   +13 more
europepmc   +1 more source

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers. [PDF]

ESMO Open
Muro K, Chin K, Maron SB, Braiteh FS, Mitani S, Hara H, Kuboki Y, Mulcahy MF, Baranda JC, Gardner FP, Jin N, Hamauchi S, Kaplan J, Gorla S, Liu S, Wozniak M, Poondru S, Dillon R, Meng C, Kondo S.   +19 more
europepmc   +1 more source

Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab. [PDF]

Bladder Cancer
Gebrael G, Jo Y, Ozay ZI, Nandakumar V, Cigliola A, Tateo V, Lin E, Ostrowski M, Sayegh N, Murdock E, Mathew Thomas V, Gupta S, Agarwal N, Swami U.   +13 more
europepmc   +1 more source

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. [PDF]

Oncologist
Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O.   +34 more
europepmc   +1 more source

Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A Podcast. [PDF]

Oncol Ther
Powles T, Lapuente M, Garmezy B.
europepmc   +1 more source

Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin-Related Dermatologic Events in Patients with Advanced Urothelial Cancer. [PDF]

Cancer Res Commun
Vlachou E, Johnson BA, McConkey DJ, Hahn NM, Jing Y, Russell S, Stairiker D, Rosen A, Casciola-Rosen LA, Hoffman-Censits J.   +9 more
europepmc   +1 more source

Enfortumab Vedotin-ejfv

American Journal of Health-System Pharmacy, 2020
openaire   +1 more source

Enfortumab vedotin therapy complicated by bullous dermatitis: A case report. [PDF]

JAAD Case Rep
Hojjatie RA, Raef HS, Mohammed TO, Henkel E, Wolner Z.   +4 more
europepmc   +1 more source